🔍

ONESOURCE - OneSource Speci.

📊 NSE: ONESOURCE 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 10:42

📢 Recent Corporate Announcements

OneSource Supports Second Generic Semaglutide Approval in Canada for Global Partners

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 04 May 2026, 08:28 AM

OneSource Specialty Pharma's partner, Orbicular, has received Health Canada approval for a generic version of Ozempic (semaglutide injection). This marks the second generic semaglutide approval in Canada, which is the world's second-largest market for this drug. OneSource serves as the end-to-end manufacturing partner and will supply the product from its US FDA-approved flagship facility in Bengaluru. This milestone follows a recent tentative US approval and successful product launches in India earlier in March 2026.

Health Canada approval secured for generic semaglutide injection in the world's second-largest market.
OneSource to provide end-to-end manufacturing from its US FDA-approved Bengaluru facility.
Follows a recent tentative US approval, strengthening the company's global CDMO positioning.
Company already supports multiple partners in India following product launches in March 2026.
Leverages a workforce of 1,600+ professionals and 5 state-of-the-art manufacturing facilities.

💡 Investors should monitor the revenue ramp-up from the Canadian market as OneSource transitions to commercial supply. The company's success in the high-growth GLP-1 (semaglutide) space validates its technical expertise in complex drug-device combinations.

OneSource Partner Dr. Reddy's Receives Health Canada Approval for Generic Semaglutide Injection

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 29 Apr 2026, 09:33 AM

OneSource Specialty Pharma's partner, Dr. Reddy's Laboratories, has received a Notice of Compliance from Health Canada for a generic version of Ozempic (Semaglutide Injection). OneSource serves as the exclusive CDMO partner for this program, providing scale-up and commercial manufacturing from its US-FDA approved flagship facility in Bengaluru. This approval validates OneSource's technical capabilities in the high-growth peptide and GLP-1 market segment. The company currently operates five state-of-the-art manufacturing facilities and employs a team of over 1,600 professionals.

Partner Dr. Reddy's receives Health Canada approval for Generic Semaglutide (Ozempic generic).
OneSource to handle commercial manufacturing at its US-FDA approved flagship Bengaluru facility.
The company operates 5 global regulatory-approved manufacturing facilities with 1,600+ professionals.
Validation of OneSource's CDMO capabilities in complex peptide development and sterile injectables.

💡 Investors should view this as a major milestone that positions OneSource as a key player in the global GLP-1 supply chain. Monitor the stock for potential revenue growth as commercial production scales up for the Canadian market.

OneSource Partner Secures Tentative US FDA Approval for Generic Ozempic (Semaglutide)

🟢 POSITIVE ⭐ 9/10

REGULATORY 📅 21 Apr 2026, 08:23 AM

OneSource Specialty Pharma's partner, Orbicular, has received tentative US FDA approval for a generic version of Ozempic (Semaglutide Injection). OneSource serves as the CDMO partner, providing end-to-end manufacturing capabilities for the product from its US-FDA approved flagship site in Bangalore. This milestone validates OneSource's technical expertise in complex peptides and drug-device combinations. The company is now positioned for commercial supply readiness in the high-growth GLP-1 market.

Tentative US FDA approval received for generic Ozempic (Semaglutide Injection) by partner Orbicular.
OneSource designated as the CDMO partner for manufacturing and global commercial supply.
Production to be centralized at OneSource's US-FDA approved flagship facility in Bangalore.
OneSource operates 5 state-of-the-art facilities with a workforce of over 1,600 professionals.

💡 Investors should monitor the timeline for final FDA approval and commercial launch, as this product addresses a multi-billion dollar global market. The development significantly enhances OneSource's profile as a high-end specialty CDMO.

OneSource Specialty Pharma Achieves 'Leader' ESG Rating of 73 from NSE Sustainability

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 16 Apr 2026, 10:16 AM

OneSource Specialty Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 73 for FY25 by NSE Sustainability Ratings & Analytics Limited. This score places the company in the 'Leader' category, reflecting strong performance in sustainability and governance practices. Notably, the rating was assigned independently based on public domain information without the company's direct engagement. This high rating is likely to enhance the company's appeal to institutional investors and ESG-focused funds.

Assigned an ESG score of 73 for the financial year FY25
Classified under the 'Leader' rating category by NSE Sustainability Ratings & Analytics
Rating was assigned independently based on public information without company solicitation
Disclosure made in compliance with SEBI Master Circular dated January 30, 2026

💡 Investors should view this as a positive validation of the company's governance and sustainability standards. While it doesn't impact immediate earnings, it may attract higher institutional interest from ESG-focused portfolios.

OneSource Specialty Pharma Allots 21,450 Equity Shares Under ESOP 2021

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Apr 2026, 08:06 PM

OneSource Specialty Pharma has approved the allotment of 21,450 equity shares to eligible employees under its Employee Stock Option Plan 2021. The shares were issued at an exercise price of INR 278 per share, which includes a premium of INR 277. This move increases the company's total paid-up share capital to INR 11,46,42,651. The new shares will rank equally with existing equity shares in all respects.

Allotment of 21,450 equity shares of face value INR 1 each upon exercise of vested options
Exercise price fixed at INR 278 per share, including a premium of INR 277
Total paid-up capital increased from 11,46,21,201 to 11,46,42,651 equity shares
The allotment was approved by the Management Committee via circular resolution on April 09, 2026

💡 This is a routine corporate action with negligible equity dilution of approximately 0.018%. Investors should treat this as a standard administrative update.

OneSource Specialty Pharma to Close Trading Window from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 04:59 PM

OneSource Specialty Pharma Limited has announced the closure of its trading window for insiders starting April 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the results are officially disclosed to the exchanges. The specific date for the board meeting to approve these results will be notified at a later date.

Trading window closure commences on Wednesday, April 1, 2026
Closure is related to the financial results for the quarter and year ended March 31, 2026
Window will reopen 48 hours after the declaration of financial results
Board meeting date for results approval to be intimated in due course

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should wait for the announcement of the board meeting date to assess the company's upcoming financial performance.

OneSource Specialty Pharma Withdraws CARE Ratings; Maintains IND A- Positive Rating

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 05 Mar 2026, 10:32 PM

OneSource Specialty Pharma has requested the withdrawal of its credit ratings from CareEdge Ratings (CARE) as part of a rationalization process. Prior to the withdrawal, CARE reaffirmed the ratings at 'CARE BBB+; Stable' for long-term facilities and 'CARE A3+' for short-term facilities. The company continues to maintain a superior credit rating of 'IND A-; Positive' from India Ratings & Research, which was reaffirmed in December 2025. This move is intended to streamline the company's external credit assessments.

CARE reaffirmed 'CARE BBB+; Stable' and 'CARE A3+' ratings before withdrawing them at the company's request.
The company continues to hold a higher 'IND A-; Positive' rating from India Ratings & Research.
Ratings were withdrawn for long-term/short-term bank facilities and non-convertible debentures.
The withdrawal is part of a periodic review and rationalization of external credit ratings.

💡 Investors should view this as a routine administrative consolidation of credit rating agencies. The maintenance of a 'Positive' outlook from India Ratings suggests a stable to improving credit profile.

OneSource Specialty Pharma to Attend Investec India Promoter & Founder Conference on March 09

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Mar 2026, 06:57 PM

OneSource Specialty Pharma Limited has announced its participation in the Investec India Promoter & Founder Conference 2026. The event is scheduled for March 09, 2026, in Mumbai, where company representatives will meet with institutional investors. The discussions will center on the company's business strategy, industry trends, and growth outlook based on publicly available information. This is a standard investor engagement activity and no unpublished price sensitive information will be shared.

Participation in Investec India Promoter & Founder Conference 2026 scheduled for March 09, 2026.
Interaction will take place in Mumbai with various institutional investors and analysts.
Discussion topics include business overview, strategy, industry trends, and growth outlook.
Compliance with Regulation 30 of SEBI (LODR) Regulations, 2015 confirmed by the company.

💡 No immediate action is required as this is a routine investor meeting. Investors should look for any subsequent investor presentations filed with the exchanges for updated insights into the company's strategy.

OneSource Pharma Gets NSE/BSE No-Objection for Merger with Steriscience and Strides Entities

🟢 POSITIVE ⭐ 8/10

M&A 📅 26 Feb 2026, 04:55 PM

OneSource Specialty Pharma has cleared a major regulatory hurdle by receiving 'No-Objection' letters from NSE and BSE for its proposed multi-entity merger. The scheme involves the absorption of Steriscience Specialties, Brooks Steriscience, Steriscience Pte. (Singapore), and Strides Pharma Services into OneSource. This consolidation is aimed at creating a larger specialty pharma platform, though it remains subject to NCLT and shareholder approvals. Investors should carefully review the mandated disclosures regarding the impact on public shareholding and the integration of accumulated losses from the merging entities.

NSE and BSE issued 'No-Objection' letters on February 25, 2026, valid for a period of six months.
The merger includes four transferor companies, including an international entity based in Singapore (Steriscience Pte. Limited).
SEBI requires prominent disclosure of the pre and post-scheme shareholding patterns for promoters and public shareholders in the upcoming notice.
The company must provide a detailed rationale for merging entities with accumulated losses and the resulting impact on OneSource's reserves.
Final implementation remains subject to approvals from the NCLT Mumbai, Singapore Courts, and respective creditors.

💡 Investors should wait for the detailed explanatory statement to assess the share-swap ratio and the financial health of the entities being absorbed. This merger is a significant step for the company's growth but requires final NCLT clearance.

OneSource Specialty Pharma Assigned ESG Score of 65.7 by SES ESG Research

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 12 Feb 2026, 04:48 PM

OneSource Specialty Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) score of 65.7 by SES ESG Research Private Limited. The rating is based on the company's performance data for the fiscal year 2024-25 available in the public domain. Notably, the company did not commission this report; SES ESG Research conducted the assessment independently. This disclosure is in compliance with the SEBI Master Circular regarding ESG ratings for listed entities.

SES ESG Research assigned an ESG score of 65.7 to the company.
The assessment is based on publicly available data from the Financial Year 2024-25.
The rating was independent and not commissioned or engaged by OneSource Specialty Pharma.
The disclosure follows the SEBI Master Circular dated January 30, 2026, regarding ESG reporting.

💡 Investors should monitor the company's ESG score relative to industry peers to assess long-term sustainability risks. No immediate action is required as this is a routine regulatory disclosure of an independent rating.

OneSource Secures SFDA Approval for Generic Ozempic in Saudi Arabia via Hikma Partnership

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 11 Feb 2026, 08:22 AM

OneSource Specialty Pharma has received approval from the Saudi Food and Drug Authority (SFDA) to commercialize a generic version of Ozempic (semaglutide) in Saudi Arabia. The company has entered into an exclusive partnership with Hikma Pharmaceuticals, the largest pharma company in the MENA region, to handle commercialization and distribution. OneSource will manufacture the product at its integrated Biologics facility in Bengaluru, India. This approval marks a significant entry into one of the world's largest markets for GLP-1 therapies, positioning the company for high-growth revenue in the metabolic health segment.

Received SFDA approval for generic semaglutide (Ozempic®) in Saudi Arabia.
Exclusive commercialization partnership with Hikma Pharmaceuticals for the MENA region.
Manufacturing to be conducted at the company's state-of-the-art Bengaluru facility.
Targeting Saudi Arabia, identified as one of the largest global markets for GLP-1 therapies.
OneSource operates 5 global manufacturing facilities with a team of over 1,600 professionals.

💡 Investors should monitor the commercial rollout and subsequent revenue contribution from the MENA region, as this establishes OneSource as a key player in the high-value GLP-1 generic market. The stock may see positive momentum given the scale of the partnership with Hikma.

Promoter Group Acquires 4.43 Lakh Shares (0.39% Stake) of OneSource Specialty Pharma

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 04 Feb 2026, 07:43 PM

Promoter group entities, Tenshi Pharmaceuticals Private Limited and Pronomz Ventures LLP, have increased their stake in OneSource Specialty Pharma by purchasing 443,906 shares from the open market. This acquisition represents approximately 0.39% of the company's total paid-up equity capital. The transactions were carried out between January 30, 2026, and February 04, 2026. Such insider buying is generally viewed as a sign of promoter confidence in the company's valuation and future growth prospects.

Promoter group acquired a total of 443,906 equity shares representing 0.39% of the company.
Tenshi Pharmaceuticals Private Limited purchased 365,000 shares across three transactions.
Pronomz Ventures LLP acquired 78,906 shares in two separate market transactions.
The acquisition was conducted through the stock market between January 30 and February 04, 2026.
Disclosures were made under SEBI Substantial Acquisition of Shares & Takeovers and Prohibition of Insider Trading regulations.

💡 Investors should take this as a positive signal of promoter commitment and confidence in the business. It may be worth monitoring the stock for further consolidation or accumulation by insiders at current levels.

OneSource Q3 FY26 Revenue Drops $10M on Regulatory Delays; Reaffirms $400M FY28 Target

🔵 WATCH ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 09:47 PM

OneSource Specialty Pharma reported a $10 million sequential revenue decline in Q3 FY26, primarily driven by deferred semaglutide approvals in the Canadian market and a strategic shift from MSAs to commercial supplies. Despite these near-term headwinds, management reiterated its FY28 guidance of $400 million in revenue and $160 million in EBITDA, excluding inorganic growth. The company is aggressively investing over INR 700 crores in capacity expansion and has doubled its flagship site workforce to prepare for a significant ramp-up expected in H2 FY27.

Q3 FY26 revenue and EBITDA declined by approximately $10 million sequentially due to deferred commercial launches.
Reiterated long-term FY28 guidance of $400 million revenue and $160 million EBITDA.
Aggressive capex of over INR 700 crores (~$100 million) is underway, with 75% of flagship site investment already committed.
Currently holding INR 250 crores in customer advances for pre-booked manufacturing capacities.
Flagship site workforce doubled year-to-date with the addition of 300 new full-time employees.

💡 Investors should focus on the H2 FY27 recovery timeline and regulatory approval milestones for semaglutide in Canada and emerging markets. While the next two quarters may remain soft, the reiterated FY28 guidance suggests significant long-term upside if execution remains on track.

Promoter Tenshi Pharmaceuticals Acquires 200,000 Shares (0.17% Stake) in OneSource Specialty

🟢 POSITIVE ⭐ 6/10

OTHER 📅 28 Jan 2026, 06:57 PM

Tenshi Pharmaceuticals Private Limited, a promoter entity of OneSource Specialty Pharma Limited, has acquired 200,000 equity shares from the open market. This transaction, completed on January 28, 2026, represents a 0.17% stake in the company's total equity capital. The acquisition was disclosed in compliance with SEBI's Substantial Acquisition of Shares and Insider Trading regulations. Promoter buying from the open market typically signals internal confidence in the company's long-term value and operational trajectory.

Tenshi Pharmaceuticals purchased 200,000 equity shares on January 28, 2026.
The acquisition accounts for 0.17% of the company's total equity share capital.
The transaction was executed via an open market purchase.
The disclosure follows SEBI (SAST) and SEBI (PIT) regulatory requirements.

💡 This insider buying is a positive indicator of promoter conviction; investors may consider this a supportive factor for the stock price. Monitor for further accumulation by promoters as a sign of sustained confidence.

OneSource Specialty Pharma Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 24 Jan 2026, 02:08 PM

OneSource Specialty Pharma Limited has released the audio recording of its earnings conference call held on January 24, 2026. The call was conducted to discuss the company's unaudited financial results for the third quarter ended December 31, 2025. This disclosure is a standard regulatory requirement under SEBI Listing Obligations and Disclosure Requirements. Investors can access the full recording via the link provided on the company's official website to gain insights into management's commentary.

Earnings call held on January 24, 2026, at 09:30 hrs IST regarding Q3 FY26 results.
Discussion centered on unaudited financial performance for the quarter ended December 31, 2025.
Audio recording link made available on the company's website for public transparency.
Compliance filing submitted under Regulation 30 and 46 of SEBI LODR Regulations.

💡 Investors should listen to the audio recording to understand management's outlook and specific performance drivers for the quarter. No immediate action is required as this is a routine procedural update.

View All ONESOURCE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

OneSource reported H1 FY26 revenue of INR 7,030 million, representing a 12% YoY growth. The proforma combined revenue for H1 FY26 reached $110 million, driven by the integration of CDMO businesses from Strides and Steriscience.

Geographic Revenue Split

The company derives 100% of its revenue from international markets, with 50% specifically coming from the US market. Production is primarily based in India and exported to regulated, growth, and access markets.

Profitability Margins

In Q2 FY26, the company reported an adjusted PAT of INR 449 million. The company achieved a break-even PBILDT for the first time in Q4 FY24, following a net loss of INR 391 crores in FY24 and INR 800 crores in FY23.

EBITDA Margin

EBITDA margin for Q2 FY26 expanded to 28%, a 506 basis point improvement YoY. Proforma combined EBITDA margin for H1 FY26 stood at 30% ($33 million EBITDA on $110 million revenue).

Capital Expenditure

The company is utilizing proceeds from a pre-listing fundraise for capex to add new capacity, with a typical lead time of two years. New capacity is expected to be operational by calendar year 2026.

Credit Rating & Borrowing

CARE Ratings reaffirmed ratings, noting that net debt to PBILDT is expected to fall below 2.5x by March 2025. Net debt for the incoming business stands at $11.5 million as of September 30, 2025, trending toward $7-$8 million.

⚙️ Operational Drivers

Import Sources

Production is centered in India, with finished products exported to overseas subsidiaries for sale in approximately 100 countries.

Capacity Expansion

Current installed capacity for the DDC (Sterile Injectables) business is 40 million units, with deliverable capacity ranging between 15 million to 20 million units. Expansion is planned for completion in CY 2026.

Raw Material Costs

Raw material price volatility contributed to margin moderation in FY22. The company uses natural hedges and forward covers to mitigate these costs and forex fluctuations.

Manufacturing Efficiency

Working capital utilization was at 90% for the 12 months ending April 2024. The company operates 7 manufacturing facilities, 4 of which are US FDA approved.

Logistics & Distribution

Distribution spans approximately 100 countries, with significant exposure to regulated markets like the USA and UK.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth will be achieved through an integrated CDMO model combining Biologics, Sterile Injectables, and Softgel. Strategies include cross-selling (12 common customers across modalities), 26 new RFP wins in a single quarter, and a material profit-share partnership with NATCO for first-to-file opportunities.

Products & Services

CDMO services for Biologics, Sterile Injectables, Softgel, and GLP-1 products.

Brand Portfolio

OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited).

New Products/Services

First Commercial Service Agreement (CSA) for a GLP-1 launch expected in FY25; 26 new RFPs added in the most recent quarter.

Market Expansion

Expansion into 100 countries with a focus on regulated markets; non-Canadian markets expected to open up from April 2026.

Strategic Alliances

Partnership with NATCO for profit-sharing on first-to-file SKUs; backing from global and local PE players.

🌍 External Factors

Industry Trends

The CDMO industry is evolving toward integrated service providers. OneSource is positioning itself as a single-source partner for Biologics and complex injectables to capture higher wallet share.

Competitive Landscape

Competes with established global CDMO players; currently has a moderate size and requires volume growth for operational efficiencies.

Competitive Moat

Moat is built on 4 USFDA-approved facilities, an integrated 'OneSource' modality model that encourages cross-selling, and a 2-year lead time barrier for competitors to add similar sterile capacity.